Phase II Study of Bevacizumab in Combination with Trastuzumab and Capecitabine as First-Line Treatment for HER-2-positive Locally Recurrent or Metastatic Breast Cancer
NAGIOS: RODERIC FUNCIONANDO

Phase II Study of Bevacizumab in Combination with Trastuzumab and Capecitabine as First-Line Treatment for HER-2-positive Locally Recurrent or Metastatic Breast Cancer

Repositori DSpace/Manakin

Phase II Study of Bevacizumab in Combination with Trastuzumab and Capecitabine as First-Line Treatment for HER-2-positive Locally Recurrent or Metastatic Breast Cancer

Mostra el registre complet de l'element

Visualització       (113.5Kb)

Exportar a Refworks
    
Martín, Miguel; Makhson, Anatoly; Gligorov, Joseph; Lichinitser, Mikhail; Lluch Hernández, Ana Perfil; Semiglazov, Vladimir; Scotto, Nana; Mitchell, Lada; Tjulandin, Sergei
Aquest document és un/a article, creat/da en: 2012
The first results from a phase II, open-label study designed to evaluate the efficacy and safety of bevacizumab in combination with trastuzumab and capecitabine as first-line therapy for patients with human epidermal growth factor receptor-2–positive locally recurrent or metastatic breast cancer are reported.

    The Oncologist Vol. 17 Issue 4: pp. 469-475
distribuït sota llicència Creative Commons de Reconeixement-NoComercial 3.0 No adaptada

Aquest element apareix en la col·lecció o col·leccions següent(s)

Mostra el registre complet de l'element

Cerca a RODERIC

Cerca avançada

Visualitza

Estadístiques